LumiraDx Limited (LMDX)
- GlobeNewswire
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company’s failure to maintain compliance with Nasdaq’s continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq’s Listing Qualifications Departm
- Zacks
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.
- Reuters
Roche to buy part of LumiraDx diagnostics platform for $295 million
Shares of LumiraDx rose about 20%, to 76 cents in aftermarket trading. The transaction is expected to close by mid-2024, after which the acquired segment will become a part of Roche's diagnostics unit, the drugmaker said. Under the terms of the agreement, Roche will pay a purchase price of $295 million at the close of the transaction.
